There was plenty of healthcare news in 2023, from Wegovy trial results to the formation of Risant Health, and the experts at Advisory Board had thoughts on them all.

1. New Wegovy trial results are out. Here's our take.

Findings from a new large-scale clinical trial of Novo Nordisk's weight-loss drug Wegovy suggest that it may reduce the risk of serious cardiovascular events by 20%. Advisory Board's Regina Lohr and Gabriela Marmolejos share their three biggest takeaways from the trial and explain how these findings could impact chronic disease prevention.

2. Kaiser+Geisinger: Our take on the formation of Risant Health

Kaiser Permanente earlier this year announced it is acquiring Geisinger Health, and Geisinger will operate independently under a new subsidiary of Kaiser called Risant Health.

3. Do new weight loss drugs pose mental health risks? Our experts weigh in.

As more people take new weight-loss drugs, such as semaglutide, there are a growing number of reports of potential side effects, including severe mental health issues — leading drug regulators in Europe to investigate the safety of these drugs.

4. Maternity care deserts in the US, mapped

In the United States, over 5.6 million pregnant people live in areas with little to no access to maternity care services, according to research from March of Dimes. Advisory Board's Gabriela Marmolejos and Lilli Silverston recommend three things stakeholders can do to reduce maternity care deserts and improve pregnancy outcomes.

5. Envision Healthcare filed for Chapter 11 bankruptcy. Here's what you need to know.

Physician staffing firm Envision Healthcare filed for Chapter 11 bankruptcy, but will "continue operating its business as usual" so that the company can "provide patients with the high-quality care they require."